An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients.
A reliable screening assay for anti-interferon beta (IFNbeta) antibodies is needed for patients with multiple sclerosis (MS) receiving IFNbeta therapy. The performance of a new ELISA method, the capture ELISA (cELISA), was assessed by comparing it to a standard IFNbeta ELISA in correlating with neutralizing antibodies measurement in 453 sera from patients with MS. The cELISA outperformed the standard ELISA, and may be a suitable screening assay for anti-IFNbeta antibodies in IFNbeta-treated patients with MS.
Pachner
Andrew R
AR
Department of Neurology and Neurosciences, UMDNJ-New Jersey Medical School, Newark 07103, USA. Pachner@umdnj.edu
D000328:Adult; D000906:Antibodies / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D016899:Interferon-beta / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000627:therapeutic use; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology*; D009500:Neutralization Tests
D000906:Antibodies; D016899:Interferon-beta